GlassScriptPhysician profile
Shelley J Halper
NPI 1922034065
$13,384.65
in general payments reported to CMS, 2019-2025
28 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $613 · 2021: $979 · 2022: $7,956 · 2023: $1,262 · 2024: $987 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.28 |
| Education | $281.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,541.03 | 2019-2022 | |
| Abbvie INC. | $1,071.75 | 2019-2025 | |
| Janssen Biotech, INC. | $679.91 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $658.41 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $528.99 | 2019-2025 | Dupixent, Libtayo |
| Solta Medical, A Division of Bausch Health US, LLC | $514.48 | 2023 | |
| Novartis Pharmaceuticals Corporation | $432.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $382.42 | 2022-2024 | Sotyktu |
| Pfizer INC. | $220.92 | 2019-2025 | |
| Leo Pharma INC. | $185.45 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $176.64 | 2020-2023 | Ilumya |
| Arcutis Biotherapeutics, INC. | $145.75 | 2023-2025 | Zoryve |
| Epi Health, LLC | $114.34 | 2022 | |
| Amgen INC. | $108.63 | 2020-2025 | Otezla |
| Ucb, INC. | $96.19 | 2019-2025 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $82.83 | 2023 | |
| Botanix Sb INC | $68.11 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $55.70 | 2023-2024 | Vtama |
| Organon LLC | $49.86 | 2025 | Vtama, Hadlima |
| Lilly USA, LLC | $49.23 | 2023 | Taltz |
| Journey Medical Corporation | $39.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.37 | 2024 | Spevigo |
| Mylan Pharmaceuticals INC. | $33.12 | 2019 | |
| Incyte Corporation | $29.84 | 2025 | Opzelura |
| Almirall LLC | $25.68 | 2024 | Klisyri |
| Sandoz INC. | $24.69 | 2020 | |
| Biofrontera INC. | $19.71 | 2020 | |
| Aclaris Therapeutics, INC. | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Halper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.